Elasmogen develops therapeutics for autoimmune diseases and cancer based on single-domain antibodies derived from sharks.

Elasmogen

Elasmogen is a therapeutic biologics company developing multi-functional products for difficult-to-treat diseases. The company has built a product pipeline that exploits the advantages of its proprietary, patent protected soloMER technology including first-in-class drug conjugates (SDC) and bi-specific products for the treatment of autoimmune diseases.
Our oncology assets include a pipeline of differentiated soloMER-targeted RadioPharmaceutical Therapies (RPT) for the treatment of solid tumour cancers.

Innovate UK

Scottish Government

Scottish Investment Bank

Deepbridge Capital

Elasmogen Ltd

Delighted to see Elasmogen highlighted, amongst all the other biopharma companies developing drugs for IBD, in Beacon and Hanson Wade's excellent webinar (link below). Our scientific team are dedicated to developing, new effective multi-functional therapies for autoimmune disease including a first-in-class soloMER drug conjugate and an orally delivered bi-specific product.
Exciting times ahead as we progress these therapies into the clinic.

#soloMERs #IBD #autoimmunedisease #lifesciences #biotech 

https://lnkd.in/eEyGjJHr

Our CEO, Caroline Barelle was delighted to contribute to Connect: Health Tech's "The Connectivity Mix: Insights on unlocking innovation: the power of the connectivity mix to transform health tech' report".

Connectivity and diversity are key to building a healthy and effective ecosystem to drive innovation. 

https://lnkd.in/grMdEj8

 #ConnectivityMix #JoinTheDots #Lifesciences #ecosystem

We had a great time hosting Harlaw Academy’s advanced higher biology students. The students participated in interactive theory and practical sessions learning from Elasmogen’s scientists about fundamental ELISA and PCR techniques.

A great piece by Helen Pattison about the positive and long-lasting impact that securing an Innovate UK Biomedical Catalyst grant had on the evolution and growth of the company and the wonderful Elasmogen team.

#ukri #bmc #lifesciences #soloMERs #biologics #scottishbusiness 

https://lnkd.in/epbBXZnZ

Our CEO, Caroline Barelle will be attending LSX's annual Inv€$tival Showcase taking place on 13th November and the Jefferies London Healthcare Conference from the 14th-16th November, London.

Please connect on the partnering portal or directly at info@elasmogen.com if you would like to meet up to learn more about our incredible soloMER technology.

https://lnkd.in/eE_QBbD

#lsx #jeffries #lifesciences #soloMERs #biologics

Yesterday The Times and ONE hosted the 3rd iteration of the Life Sciences Summit at the beautiful Old Aberdeen campus of The University of Aberdeen. 
Elasmogen's Chief Executive Caroline Barelle and BGF investor Lucy Edwardes-Jones shared with the audience their discussion about long-term funding relationships. Thanks Caroline and Lucy for the great panel and engaging conversation!
All discussions and panels from the Life Sciences Summit were recorded and will be shared soon.

https://lnkd.in/eRpQpXm6

COM:ELASMOGEN

Elasmogen

Analysis Not Available